Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
An agreement between industry and authorities in effect from April last year is already having a major effect in ensuring Canadian generics prices are similar to those in other developed markets, an official report shows.
July saw UK generic trade price rises peak at a 100% increase for oxytetracycline 250mg tablets, while hydrocortisone 20mg tablets saw their average price plummet by two-thirds, according to the latest figures from WaveData.
Panellists at the UK’s Westminster Health Forum conference on Biosimilars in the NHS united over concerns of a no-deal Brexit and what it would mean for generics and biosimilars producers.
The latest GDUFA science and research findings have been reported by the FDA.
The UK’s market of 65m patients is gearing up for several new biosimilars to hit the market, with 15 biologic brands set to lose exclusivity in Europe over the next four to five years. However, challenges remain.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.